论文部分内容阅读
目的:观察山莨菪碱(654-2)辅助治疗儿童支原体肺炎的临床疗效。方法:将168例支原体肺炎患儿随机分为实验组(n=90)和对照组(n=78)。实验组在以阿奇霉素静脉滴注5d基础上,合用654-2穴位注射;对照组以阿奇霉素静脉滴注5d。分析和比较两组患儿的治疗效果、不良反应等情况。结果:两组患儿在发热、咳嗽、气喘、肺部啰音等主要症状、体征消失时间比较,实验组明显短于对照组(P<0.05);实验组整体显效率(84.5%)高于对照组(64.1%)(P<0.01);两组不良反应比较,实验组不良反应发生率明显低于对照组(P<0.01)。结论:阿奇霉素联合654-2穴位注射治疗能明显改善临床症状,减少不良反应,值得临床推广应用。
Objective: To observe the clinical efficacy of anisodamine (654-2) in the treatment of mycoplasma pneumonia in children. Methods: 168 children with mycoplasmal pneumonia were randomly divided into experimental group (n = 90) and control group (n = 78). The experimental group was treated with intravenous infusion of azithromycin for 5 days on the basis of 654-2 point injection, while the control group received intravenous infusion of azithromycin for 5 days. Analysis and comparison of two groups of children with treatment effects, adverse reactions and so on. Results: The two groups of children in the fever, cough, asthma, pulmonary rales and other major symptoms, signs disappeared compared with the experimental group was significantly shorter than the control group (P <0.05); experimental group overall effective rate (84.5% (64.1%) in the control group (P <0.01). Compared with the adverse reactions in the two groups, the incidence of adverse reactions in the experimental group was significantly lower than that in the control group (P <0.01). Conclusion: Azithromycin combined with 654-2 point injection can significantly improve clinical symptoms and reduce adverse reactions, which is worthy of clinical application.